MHRA: Issues Field Safety Notices 14-18 September 2026 for Medical Devices

• The MHRA issued several Field Safety Notices between September 14 and 18, 2026, concerning various medical devices.
• Affected devices include a Cardiac defect occluder, an Intracardiac circulatory assist axial-pump catheter, orthopedic instruments, endoscopic needles, MRI systems, and radiological PACS software.
• Recipients of FSNs directly from manufacturers are legally required to act on the notices, while the MHRA publishes them for informational purposes.
• Questions about specific FSNs should be directed to the respective device manufacturers, not the MHRA.
• Legal and compliance professionals must review these notices to ensure immediate and compliant action, mitigating potential liability and regulatory breaches.

Lawyers and compliance officers must promptly review these MHRA Field Safety Notices to identify any relevant medical devices and ensure their clients or organizations are taking immediate, compliant action as required, mitigating potential liability and regulatory breaches.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a series of critical Field Safety Notices (FSNs) between 14 and 18 September 2026, highlighting potential issues with various medical devices. These MHRA Field Safety Notices 14-18 September 2026 cover a diverse range of products, from implantable cardiac devices to diagnostic software and surgical instruments, underscoring the ongoing need for vigilance in medical device compliance UK.

Among the devices identified is a Cardiac defect occluder, specifically models 9-ACP2-007-016, 9-ACP2-007-018, 9-ACP2-007-020, 9-ACP2-007-022, 9-ACP2-010-025, 9-ACP2-010-028, 9-ACP2-010-031, and 9-ACP2-010-034, associated with MHRA reference 40786527 2026/009/010/601/054. Another significant alert pertains to an Intracardiac circulatory assist axial-pump catheter, affecting models 0042-0040, 0042-0010, and 0042-0000, under MHRA reference 40838299 2026/008/018/601/067. The presence of a Cardiac defect occluder FSN and an Intracardiac catheter safety notice indicates concerns in high-risk cardiovascular applications.

Further notices include Orthopedic Prosthetics Instruments, specifically reusable types, with MHRA references 40870441 2026/009/021/601/065 and 40846082 2026/009/017/601/105, the latter also accompanied by Distributor and HCP Letters. A general-purpose endoscopic needle designed for single-use is also subject to an FSN, referenced as 40833994 2026/009/016/601/075. The list continues with a Full-body MRI system featuring a superconducting magnet (MHRA references 40820852 2026/009/015/601/082 and 40837295 2026/009/016/601/074), and Radiological PACS software, which has multiple associated MHRA references: 40833327 2026/009/017/601/004, 40843859 2026/009/017/601/075 (with Customer and Distributor Letters), and 40699134 2026/008/020/601/032. Finally, a notice regarding Multiple gastrointestinal pathogen nucleic acid is listed under MHRA reference 40824074 2026/007/003/601/095. These UK medical device recalls September 2026 highlight a broad spectrum of potential safety issues.

The MHRA's publication of these safety alerts medical devices serves an informational purpose, making the wider healthcare community aware of potential hazards or necessary corrective actions. While the agency disseminates this information, the primary responsibility for addressing the issues lies with the manufacturers. Any entity receiving a Field Safety Notice directly from a manufacturer is legally obligated to take immediate and appropriate action as specified within the notice.

It is crucial for healthcare providers and distributors to understand that the MHRA acts as a central point for disseminating these alerts, but direct engagement regarding specific FSNs should be directed to the respective device manufacturer. The agency maintains an extensive archive of these notices, with current FSNs readily available, along with lists published since January 2020 and November 2014. Older FSNs, predating November 2014, are accessible through the National Archives website, ensuring a comprehensive record of past safety communications.

The recent influx of MHRA Field Safety Notices 14-18 September 2026 carries significant implications for legal and compliance professionals within the healthcare sector. These alerts are not merely informational; they trigger mandatory actions that, if neglected, could lead to substantial legal and regulatory repercussions. Organizations must have robust systems in place to promptly identify any relevant medical devices within their inventory or supply chain that are subject to these notices.

Lawyers and compliance officers must promptly review these MHRA Field Safety Notices to identify any relevant medical devices and ensure their clients or organizations are taking immediate, compliant action as required, mitigating potential liability and regulatory breaches. This proactive approach is essential for maintaining medical device compliance UK and safeguarding patient safety. Failure to act on an FSN can expose organizations to regulatory penalties, product liability claims, and reputational damage. The detailed nature of these MHRA safety alerts medical devices, including specific models and MHRA references, necessitates a thorough and precise response from all stakeholders involved in the distribution, use, or maintenance of these devices.

Lawyers and compliance officers must promptly review these MHRA Field Safety Notices to identify any relevant medical devices and ensure their clients or organizations are taking immediate, compliant action as required, mitigating potential liability and regulatory breaches.

Source: Original reporting via UK government publication.